Esperion Therapeutics, Inc. — fact timeline

Esperion Therapeutics, Inc. shareholders approved Amendment to 2022 Plan to increase authorized shares by 7,000,000 at the 2026-05-28 meeting.

“For Against Abstain Broker Non-Votes 108,150,213 22,489,001 454,840 46,114,802”

Esperion Therapeutics, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm at the 2026-05-28 meeting.

“ective successors are duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”), (ii) to approve the non-binding advisory resolution on the compensation of the Company’s named executive officers (“Proposal 2”), (iii) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 3”), and (iv) to approve an amendment to the 2022 Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the 2022 Plan by 7,000,000 shares ("Proposal 4").”

Esperion Therapeutics, Inc. shareholders approved Non-binding advisory resolution on the compensation of the Company’s named executive officers at the 2026-05-28 meeting.

“'s Board of Directors, each to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”), (ii) to approve the non-binding advisory resolution on the compensation of the Company’s named executive officers (“Proposal 2”), (iii) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 3”), and (iv) to approve an amendment to the 2022 Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the 2022 Plan by 7,000,000 shares ("Proposal 4").”

Esperion Therapeutics, Inc. shareholders approved Election of Class I directors at the 2026-05-28 meeting.

“J. Martin Carroll 105,082,565 26,011,489 46,114,802 Sheldon L. Koenig 109,672,941 21,421,113 46,114,802”

Esperion Therapeutics, Inc. entered into Agreement and Plan of Merger with Essence Parent Inc. valued at Merger consideration of $3.16 per share plus contingent value rights (effective 2026-05-01).

“On May 1, 2026, Esperion Therapeutics, Inc. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Essence Parent Inc., a Delaware corporation (“ Parent ”), and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ MergerCo ”), pursuant to which, subject to the terms and conditions thereof, MergerCo will merge with and into the Company with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the “ Merger ”).”

Esperion Therapeutics, Inc. incurred term loan of $25,000,000 with GLAS USA LLC and GLAS Americas LLC, collectively, as the administrative agent for the lenders.

“The First Amendment amends that certain Credit Agreement, dated as of December 13, 2024 (the “Existing Credit Agreement” and as amended by the Amendment, the “Credit Agreement”), by and among the Company, the Administrative Agent and the lenders party thereto. The Amendment, among other things, provides for the incurrence of additional term loans in an aggregate principal amount of $25,000,000 (the “First Amendment Term Loans”)”

Esperion Therapeutics, Inc. entered into First Amendment to Credit Agreement with GLAS USA LLC and GLAS Americas LLC, collectively, as the administrative agent (effective 2026-04-02).

“On April 2, 2026 (the “Closing Date”), Esperion Therapeutics, Inc. (the “Company”) entered into the First Amendment to Credit Agreement (the “Amendment”), by and among the Company, as the borrower, the lenders party thereto and GLAS USA LLC and GLAS Americas LLC, collectively, as the administrative agent for the lenders (the “Administrative Agent”).”

Esperion Therapeutics, Inc. completed an acquisition involving Corstasis Therapeutics Inc. for The aggregate up-front consideration for the transactions contemplated by the Merger Agreement (the “Transactions”) was $75,000,000 in cash, subject to customar (closed 2026-04-02).

“On March 2, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”) and certain other parties described therein. Pursuant to the Merger Agreement, on April 2, 2026, the Company completed the merger of Corstasis with and into Merger Sub, with Corstasis surviving the merger as a wholly owned subsidiary of the Company (the “Merger”). The aggregate up-front consideration for the transactions contemplated by the Merger Agreement (the “Transactions”) was $75,000,000 in cash, subject to customary adjustments and a post-closing purchase price adjustment. In addition, the equityholders of Corstasis are entitled to receive: (i) milestone payments up to an aggregate amount equal to $180,000,000 if certain regulatory approval or commercial sales milestones are achieved and (ii) r”

Esperion Therapeutics, Inc. entered into Agreement and Plan of Merger with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”) valued at $75,000,000 (effective 2026-03-02).

“On March 2, 2026, Esperion Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”).”

Eric Warren departed as Chief Commercial Officer at Esperion Therapeutics, Inc..

“Eric Warren was stepping down from his position as Chief Commercial Officer of the Company, effective as of April 18, 2025.”

Robert E. Hoffman was elected as Director and Chairperson of the Audit Committee at Esperion Therapeutics, Inc..

“On April 1, 2025, upon the recommendation of the Nominating and Corporate Governance Committee, the Board elected Robert E. Hoffman to the Board, effective April 1, 2025.”

Antonio M. Gotto, Jr., M.D., D.Phil. resigned as Director at Esperion Therapeutics, Inc..

“On April 1, 2025, Antonio M. Gotto, Jr., M.D., D. Phil. notified the Board of the Company of his decision to resign from the Board, including his position as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective June 1, 2025.”

Nicole Vitullo resigned as Director at Esperion Therapeutics, Inc..

“On April 1, 2025, Nicole Vitullo notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) of her decision to resign from the Board, including her positions as a member of the Audit Committee of the Board (the “Audit Committee”) and Compliance Committee of the Board, effective June 1, 2025.”

JoAnne Foody changed role as Chief Medical Officer at Esperion Therapeutics, Inc..

“JoAnne Foody will be transitioning from her role as the Company’s Chief Medical Officer and that her employment with the Company will end on or before September 16, 2024”

Esperion Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $137.7 million.

“Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million”